ToxSci Advance Access published online on May 11, 2005
Toxicological Sciences, doi:10.1093/toxsci/kfi190
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Cell Biology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73190
* To whom correspondence should be addressed. Trivalent inorganic arsenic (arsenite, arsenic trioxide, As(III)) is a primary contaminant of groundwater supplies worldwide. As(III), marketed as trisenox, is also an FDA approved agent to treat cancer It has been previously shown by our laboratory that As(III) administered at doses lower than a therapeutic anti-cancer dose results in an increase in tumor formation and blood vessel density of tumors. In this work it was found that chronic administration of As(III) approaching the EPA action level of 10 ppb given in the drinking water of mice five weeks prior to B16-F10 melanoma implantation increased the growth rate of primary tumors and the number of metastases to the lung. Further, levels of arsenic in the tumor and lung were found to be much greater than those in the blood and similar to pro-angiogenic As(III) doses. Levels of hypoxia inducible factor-1 1These two authors contributed equally to this work.
Received April 20, 2005
Accepted April 28, 2005
Carcinogenicity
Role of HIF signaling on tumorigenesis in response to chronic low dose arsenic administration
2 Center for Environmental Health Sciences and Department of Pharmacology and Toxicology, Dartmouth Medical School, Hanover, NH 03755
Michael A. Ihnat, E-mail: michael-ihnat{at}ouhsc.edu
![]()
Abstract
(HIF-1
) and vascular endothelial growth factor (VEGF) surrounding the blood vessels in the tumors of the As(III)-treated mice were also found to be increased. Exposure of isolated B16-F10 tumor cells to chronic (three or seven day) but not acute (4 h) low dose As(III) was found to increase HIF-1
expression and secretion of VEGF. Finally, co-administration of an inhibitor of HIF (YC-1) or a VEGFR-2 kinase inhibitor (SU5416) was found to antagonize the pro-angiogenic effects of low dose As(III). Together, these results suggest that chronic exposure to low dose As(III) could stimulate growth of tumors through a HIF-dependent stimulation of angiogenesis.![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
A. C. Straub, L. R. Klei, D. B. Stolz, and A. Barchowsky Arsenic Requires Sphingosine-1-Phosphate Type 1 Receptors to Induce Angiogenic Genes and Endothelial Cell Remodeling Am. J. Pathol., May 1, 2009; 174(5): 1949 - 1958. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Kaczmarek, R. E. Cachau, I. A. Topol, K. S. Kasprzak, A. Ghio, and K. Salnikow Metal Ions-Stimulated Iron Oxidation in Hydroxylases Facilitates Stabilization of HIF-1{alpha} Protein Toxicol. Sci., February 1, 2009; 107(2): 394 - 403. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Hays, R. C. Lantz, L. S. Rodgers, J. J. Sollome, R. R. Vaillancourt, A. S. Andrew, J. W. Hamilton, and T. D. Camenisch Arsenic-Induced Decreases in the Vascular Matrix Toxicol Pathol, October 1, 2008; 36(6): 805 - 817. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. C. Prozialeck, J. R. Edwards, D. W. Nebert, J. M. Woods, A. Barchowsky, and W. D. Atchison The Vascular System as a Target of Metal Toxicity Toxicol. Sci., April 1, 2008; 102(2): 207 - 218. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. R. Klei and A. Barchowsky Positive Signaling Interactions between Arsenic and Ethanol for Angiogenic Gene Induction in Human Microvascular Endothelial Cells Toxicol. Sci., April 1, 2008; 102(2): 319 - 327. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. R. Shaw, K. Gabor, E. Hand, A. Lankowski, L. Durant, R. Thibodeau, C. R. Stanton, R. Barnaby, B. Coutermarsh, K. H. Karlson, et al. Role of glucocorticoid receptor in acclimation of killifish (Fundulus heteroclitus) to seawater and effects of arsenic Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2007; 292(2): R1052 - R1060. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Lopez-Lazaro HIF-1: hypoxia-inducible factor or dysoxia-inducible factor? FASEB J, May 1, 2006; 20(7): 828 - 832. [Abstract] [Full Text] [PDF] |
||||




